|
There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes.
|
Aug 2013
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes-specific risk stratification: Are we putting the cart before the horse?
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes, or are they?
|
Nov 2016
|
Blood Rev
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy for lower-risk MDS
|
Dec 2020
|
Hematology. American Society of Hematology. Education Program
|
myelodysplastic syndromes (MDS)
|
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
|
Apr 2023
|
Current Hematologic Malignancy Reports
|
myelodysplastic syndromes (MDS)
|
|
Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia.
|
Jun 2013
|
J Exp Med
|
aplastic anemia
|
|
The value of survival gains in myelodysplastic syndromes.
|
Jan 2017
|
Am J Manag Care
|
myelodysplastic syndromes (MDS)
|
|
The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
|
May 2015
|
Int J Lab Hematol
|
myelodysplastic syndromes (MDS)
|
|
The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells
|
Feb 2012
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
